D

Devyser Diagnostics AB
STO:DVYSR

Watchlist Manager
Devyser Diagnostics AB
STO:DVYSR
Watchlist
Price: 136.5 SEK 1.49% Market Closed
Market Cap: 2.3B SEK
Have any thoughts about
Devyser Diagnostics AB?
Write Note

Devyser Diagnostics AB
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Devyser Diagnostics AB
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
D
Devyser Diagnostics AB
STO:DVYSR
Other Current Liabilities
kr11.2m
CAGR 3-Years
14%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Other Current Liabilities
kr51.3m
CAGR 3-Years
19%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Other Current Liabilities
kr91.1m
CAGR 3-Years
42%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Other Current Liabilities
kr192m
CAGR 3-Years
48%
CAGR 5-Years
27%
CAGR 10-Years
9%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Other Current Liabilities
kr6.4B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
24%
BioArctic AB
STO:BIOA B
Other Current Liabilities
kr49.3m
CAGR 3-Years
-17%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
No Stocks Found

Devyser Diagnostics AB
Glance View

Market Cap
2.3B SEK
Industry
Biotechnology

Devyser Diagnostics AB engages in the development, manufacture and sale of kits for genetic testing in routine diagnostics. The company is headquartered in Hagersten, Stockholm. The company went IPO on 2021-12-10. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The firm has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The firm provides its products in more than 45 countries.

DVYSR Intrinsic Value
123.02 SEK
Overvaluation 10%
Intrinsic Value
Price
D

See Also

What is Devyser Diagnostics AB's Other Current Liabilities?
Other Current Liabilities
11.2m SEK

Based on the financial report for Dec 31, 2023, Devyser Diagnostics AB's Other Current Liabilities amounts to 11.2m SEK.

What is Devyser Diagnostics AB's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
54%

Over the last year, the Other Current Liabilities growth was -28%. The average annual Other Current Liabilities growth rates for Devyser Diagnostics AB have been 14% over the past three years , 54% over the past five years .

Back to Top